Evgeniya V. Tavlueva
Research Subjects
Evgeniya V. Tavlueva has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Svetlana A. Berns
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
4 shared publications - Arnold E. Markarov
Inozemtsev City Clinical Hospital of the Department of Health of Moscow
3 shared publications - E. V. Zernova
Inozemtsev Municipal Clinical Hospital
3 shared publications - Olga V. Filon
Joint-Stock Company “R-Pharm
3 shared publications - Alina S. Agafina
City Hospital №. 40
2 shared publications - Anna A. Panfilova
City Clinical Hospital named after F.I. Inozemtsev
2 shared publications
Latest Publications
- Open Access
- 17 February 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (1) , 57-66
Thrombolytic therapy with Revelisa in ischemic stroke: results of the PRIMA international multicenter observational study
Thrombolytic therapy (TLT) of ischemic stroke (IS) with alteplase within the first 4.5 hours from the onset of symptoms is the most effective and proven method of treatment.Objective: to evaluate the safety and efficacy of TLT with Revelisa (alteplase) in IS in real-world clinical practice.Material and methods. The results of TLT with Revelisa were analyzed in 1181 patients with IS: 616 (52.2%) women and 565 (47.8%) men (mean age 68.28±12.56 years), of which 140 (11.9%) with staged reperfusion. The mean time from disease onset to TLT was 2.58±0.83 hours. The Heidelberg classification was used to assess hemorrhages during neuroimaging. Symptomatic hemorrhagic transformation (HT) was defined according to ECASS III criteria. The study group was characterized by high comorbidity: arterial hypertension (96.9%), ischemic heart disease (56.7%), chronic heart failure (55.8%) and cardiac arrhythmias (33.3%) were most common; diabetes mellitus was present in 23% of patients. IS occurred repeatedly in 15.4% of cases.Results. An improvement of 4 points or more on the NIHSS scale one day after TLT was observed in 41% of patients. The dynamics of the decrease in neurological symptoms one day later and at the time of discharge were statistically significant (pConclusion. The results of the PRIMA study confirm the high level of efficacy and safety of Revelisa in patients with IS, including during staged reperfusion. The data obtained are consistent with the published registry studies on alteplase in IS.
- 17 February 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (1) , 57-66
Open AccessThrombolytic therapy with Revelisa in ischemic stroke: results of the PRIMA international multicenter observational study
Thrombolytic therapy (TLT) of ischemic stroke (IS) with alteplase within the first 4.5 hours from the onset of symptoms is the most effective and proven method of treatment.Objective: to evaluate the safety and efficacy of TLT with Revelisa (alteplase) in IS in real-world clinical practice.Material and methods. The results of TLT with Revelisa were analyzed in 1181 patients with IS: 616 (52.2%) women and 565 (47.8%) men (mean age 68.28±12.56 years), of which 140 (11.9%) with staged reperfusion. The mean time from disease onset to TLT was 2.58±0.83 hours. The Heidelberg classification was used to assess hemorrhages during neuroimaging. Symptomatic hemorrhagic transformation (HT) was defined according to ECASS III criteria. The study group was characterized by high comorbidity: arterial hypertension (96.9%), ischemic heart disease (56.7%), chronic heart failure (55.8%) and cardiac arrhythmias (33.3%) were most common; diabetes mellitus was present in 23% of patients. IS occurred repeatedly in 15.4% of cases.Results. An improvement of 4 points or more on the NIHSS scale one day after TLT was observed in 41% of patients. The dynamics of the decrease in neurological symptoms one day later and at the time of discharge were statistically significant (pConclusion. The results of the PRIMA study confirm the high level of efficacy and safety of Revelisa in patients with IS, including during staged reperfusion. The data obtained are consistent with the published registry studies on alteplase in IS.
- Open Access
- 30 April 2024
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 64 (4) , 72-78
Features of the Course of Arterial Hypertension in the Era of the COVID-19 Pandemic: Common Pathogenetic Links Between Hypertension and SARS-CoV-2
The aim of this review was to present the mechanism of infection with severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) and its possible effect on the course of arterial hypertension. Another aim was to evaluate the relationship of the renin-angiotensin-aldosterone system with the pathogenetic stages of infection caused by SARS-CoV-2 virus.
- 30 April 2024
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 64 (4) , 72-78
Open AccessFeatures of the Course of Arterial Hypertension in the Era of the COVID-19 Pandemic: Common Pathogenetic Links Between Hypertension and SARS-CoV-2
The aim of this review was to present the mechanism of infection with severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) and its possible effect on the course of arterial hypertension. Another aim was to evaluate the relationship of the renin-angiotensin-aldosterone system with the pathogenetic stages of infection caused by SARS-CoV-2 virus.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 27 (6)
Neurological complications in patients underwent COVID-19
Despite the fact that COronaVIrus Disease 2019 (COVID-19) primarily affects the respiratory system, it is known that many so-called post-COVID patients, who have no symptoms of acute infectious process, have long-term physiological, psychological and cognitive disorders. The most common complications are neurological. The article considers pathogenetic variants of affect with the Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) of the central and peripheral nervous system, as well as neurological clinical manifestations in both acute and long-term periods of COVID-19. The analysis of literature data for the period of the pandemic from 2020 to 2023 was conducted.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 27 (6)
Neurological complications in patients underwent COVID-19
Despite the fact that COronaVIrus Disease 2019 (COVID-19) primarily affects the respiratory system, it is known that many so-called post-COVID patients, who have no symptoms of acute infectious process, have long-term physiological, psychological and cognitive disorders. The most common complications are neurological. The article considers pathogenetic variants of affect with the Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) of the central and peripheral nervous system, as well as neurological clinical manifestations in both acute and long-term periods of COVID-19. The analysis of literature data for the period of the pandemic from 2020 to 2023 was conducted.
- Open Access
- 27 January 2024
- Published by "MedINK" Publishing House in Russian journal of neurosurgery
- Vol. 25 (4) , 87-95
Traumatic injury of vertebral artery complicated by formation of a giant pseudoaneurysm of the V3 segment (clinical observation and literature review)
Traumatic vertebral artery injury (TVAI) is a rare but severe pathology which can be associated both with penetrating injury of the neck and blunt or unclassified injury. Injury of the vertebral artery, especially due to gunshot or knife wounds, causes severe condition of the patients, development of a wide spectrum of complications including life-threatening, high rates of disabilities and mortality.There is no consensus on the treatment tactics for this pathology. Open surgery as the first stage of surgical intervention can be used in a limited number of cases. X-ray endovascular techniques of TVAI treatment are considered to be preferable.We present a clinical case of a 27‑year-old patient with TVAI caused by a penetrating gunshot wound of the neck and complicated by formation of a giant pseudoaneurysm of the V3 segment of the vertebral artery. Two-stage combination treatment of TVAI was performed using endovascular and open surgical techniques.Descriptions of TVAI cases are rare, and further accumulation and analysis of corresponding data and proposals on treatment of the patients with TVAI will help to formulate precise algorithms of doctors’ actions and optimize treatment tactics.
- 27 January 2024
- Published by "MedINK" Publishing House in Russian journal of neurosurgery
- Vol. 25 (4) , 87-95
Open AccessTraumatic injury of vertebral artery complicated by formation of a giant pseudoaneurysm of the V3 segment (clinical observation and literature review)
Traumatic vertebral artery injury (TVAI) is a rare but severe pathology which can be associated both with penetrating injury of the neck and blunt or unclassified injury. Injury of the vertebral artery, especially due to gunshot or knife wounds, causes severe condition of the patients, development of a wide spectrum of complications including life-threatening, high rates of disabilities and mortality.There is no consensus on the treatment tactics for this pathology. Open surgery as the first stage of surgical intervention can be used in a limited number of cases. X-ray endovascular techniques of TVAI treatment are considered to be preferable.We present a clinical case of a 27‑year-old patient with TVAI caused by a penetrating gunshot wound of the neck and complicated by formation of a giant pseudoaneurysm of the V3 segment of the vertebral artery. Two-stage combination treatment of TVAI was performed using endovascular and open surgical techniques.Descriptions of TVAI cases are rare, and further accumulation and analysis of corresponding data and proposals on treatment of the patients with TVAI will help to formulate precise algorithms of doctors’ actions and optimize treatment tactics.
- Open Access
- 11 October 2023
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (8) , 652-657
Opportunities to improve the prognosis of the course of COVID-19 for at-risk patients
Aim. To evaluate the efficacy and safety of a combination of virus neutralizing monoclonal antibodies in the treatment of patients with confirmed COVID-19 and risk factors for disease progression and severe disease course. Materials and methods. The study was carried out in the Sokolniki temporary hospital of the Inozemtsev City Clinical Hospital. A retrospective comparative case-control study included 400 patients hospitalized for confirmed COVID-19 infection from November 01, 2022 to March 31, 2023. Patients were divided into two groups depending on the treatment given: the first control group (n=200) and the second group (n=200), where patients received a single intramuscular injection of tixagevimab + cilgavimab within the first days of hospitalization. Results. When analyzing the concomitant pathology, C-reactive protein level and CT scans at the time of hospitalization, it was revealed that patients in the tixagevimab + cilgavimab treatment group were more severe compared to the control group. On the 2nd day of hospitalization, there was a decrease in the level of C-reactive protein in the control group by 36.2%, in the group receiving tixagevimab + cilgavimab by 45.2%; p0.05. Standard treatment was supplemented with antibacterial therapy in 47 (23.5%) patients of the first group and in 32 (16.0%) patients of the second group, which was due to the accession of bacterial infection; p0.05. Significant differences were found in the duration of hospitalization, which averaged 8.00.21 bed-days in group 1 and 6.40.13 (p0.05) bed-days in group 2. No adverse reactions to intramuscular injection of tixagevimab + cilgavimab were detected. Conclusion. The use of a combination of neutralizing monoclonal antibodies in patients with COVID-19 reduce the average bed-day in hospitalization of patients with comorbid pathology and/or immunodeficiencies and high risk of progression of infection.
- 11 October 2023
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (8) , 652-657
Open AccessOpportunities to improve the prognosis of the course of COVID-19 for at-risk patients
Aim. To evaluate the efficacy and safety of a combination of virus neutralizing monoclonal antibodies in the treatment of patients with confirmed COVID-19 and risk factors for disease progression and severe disease course. Materials and methods. The study was carried out in the Sokolniki temporary hospital of the Inozemtsev City Clinical Hospital. A retrospective comparative case-control study included 400 patients hospitalized for confirmed COVID-19 infection from November 01, 2022 to March 31, 2023. Patients were divided into two groups depending on the treatment given: the first control group (n=200) and the second group (n=200), where patients received a single intramuscular injection of tixagevimab + cilgavimab within the first days of hospitalization. Results. When analyzing the concomitant pathology, C-reactive protein level and CT scans at the time of hospitalization, it was revealed that patients in the tixagevimab + cilgavimab treatment group were more severe compared to the control group. On the 2nd day of hospitalization, there was a decrease in the level of C-reactive protein in the control group by 36.2%, in the group receiving tixagevimab + cilgavimab by 45.2%; p0.05. Standard treatment was supplemented with antibacterial therapy in 47 (23.5%) patients of the first group and in 32 (16.0%) patients of the second group, which was due to the accession of bacterial infection; p0.05. Significant differences were found in the duration of hospitalization, which averaged 8.00.21 bed-days in group 1 and 6.40.13 (p0.05) bed-days in group 2. No adverse reactions to intramuscular injection of tixagevimab + cilgavimab were detected. Conclusion. The use of a combination of neutralizing monoclonal antibodies in patients with COVID-19 reduce the average bed-day in hospitalization of patients with comorbid pathology and/or immunodeficiencies and high risk of progression of infection.
- Open Access
- 7 September 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (2) , 5602
Changes of natriuresis and prediction of cardiovascular events in patients with type 2 diabetes and decompensated heart failure over therapy with sodium-glucose cotransporter 2 inhibitors and standard diuretic therapy
Aim. To evaluate the influence and changes of clinical and water-electrolyte parameters on the risk of cardiovascular events in the early period after decompensated heart failure (HF) in patients with type 2 diabetes (T2D), taking into account the influence of standard diuretic therapy and diuretic therapy in combination with sodium-glucose cotransporter 2 (SGLT-2) inhibitors.Material and methods. The study included 119 patients with type 2 diabetes and class III-IV HF. The duration of diagnosed HF at the time of enrollment was 6,9±1,1 years.Patients who met the inclusion criteria at the time of hospital admission were randomized into a group of standard therapy for decompensated HF (control group) and a group of combined diuretic therapy — loop diuretics + SGLT-2 inhibitors (main group).Results. Against the background of combined diuretic therapy with SGLT-2 inhibitors, a significant increase in diuresis was achieved, starting from the 2nd day: on day 2 — in the main group 1,342,83±159,74 ml/day and 1,250,17±134,53 ml/day in the control group (p=0,001, 95% confidence interval (CI)), on day 3, in the main — 1,895,17±249,95 ml/day, and in the control — 1,723,78±252,49 ml/day (p=0,004, 95% CI), on day 4, in the main — 2,382,50±246,29 ml/day and in the control — 2,124,83±2,86,44 ml/day (p=0,000002, 95% CI), on day 5, in the main — 2,785,50±282,38 ml/day and in the control group 2,458,39±273,36 ml/day (pConclusion. In patients with type 2 diabetes hospitalized for decompensated HF, therapy with SGLT-2 inhibitors + loop diuretics lead to a significantly greater diuresis, natriuresis and a greater decrease in extracellular fluid volume. A significant inverse relationship was found between the extracellular fluid volume and natriuresis level on day 5. Dapagliflozin effectiveness in edema, assessed by natriuresis level on day of treatment, is identical to the empagliflozin.
- 7 September 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (2) , 5602
Open AccessChanges of natriuresis and prediction of cardiovascular events in patients with type 2 diabetes and decompensated heart failure over therapy with sodium-glucose cotransporter 2 inhibitors and standard diuretic therapy
Aim. To evaluate the influence and changes of clinical and water-electrolyte parameters on the risk of cardiovascular events in the early period after decompensated heart failure (HF) in patients with type 2 diabetes (T2D), taking into account the influence of standard diuretic therapy and diuretic therapy in combination with sodium-glucose cotransporter 2 (SGLT-2) inhibitors.Material and methods. The study included 119 patients with type 2 diabetes and class III-IV HF. The duration of diagnosed HF at the time of enrollment was 6,9±1,1 years.Patients who met the inclusion criteria at the time of hospital admission were randomized into a group of standard therapy for decompensated HF (control group) and a group of combined diuretic therapy — loop diuretics + SGLT-2 inhibitors (main group).Results. Against the background of combined diuretic therapy with SGLT-2 inhibitors, a significant increase in diuresis was achieved, starting from the 2nd day: on day 2 — in the main group 1,342,83±159,74 ml/day and 1,250,17±134,53 ml/day in the control group (p=0,001, 95% confidence interval (CI)), on day 3, in the main — 1,895,17±249,95 ml/day, and in the control — 1,723,78±252,49 ml/day (p=0,004, 95% CI), on day 4, in the main — 2,382,50±246,29 ml/day and in the control — 2,124,83±2,86,44 ml/day (p=0,000002, 95% CI), on day 5, in the main — 2,785,50±282,38 ml/day and in the control group 2,458,39±273,36 ml/day (pConclusion. In patients with type 2 diabetes hospitalized for decompensated HF, therapy with SGLT-2 inhibitors + loop diuretics lead to a significantly greater diuresis, natriuresis and a greater decrease in extracellular fluid volume. A significant inverse relationship was found between the extracellular fluid volume and natriuresis level on day 5. Dapagliflozin effectiveness in edema, assessed by natriuresis level on day of treatment, is identical to the empagliflozin.
- Open Access
- 5 September 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (7) , 3573
Results of a pilot clinical trial of the safety and efficacy of an original glycoprotein IIb/IIIa receptor inhibitor in acute coronary syndrome
Aim. To study the safety and efficacy of Angipure in acute ST-segment elevation coronary syndrome (STE-ACS) and high-risk percutaneous transluminal coronary angioplasty (PTCA) compared with eptifibatide.Material and methods. The study included 157 patients with STE-ACS. High-risk PTCA included massive or total coronary artery thrombosis, noreflow/slow-reflow phenomenon, and acute stent thrombosis. Fifty-five people received Angipure at a dose of 0,72 mg/kg, 52 — at a dose of 0,40 mg/kg, while 50 patients received eptifibatide (Integrilin). We conducted clinical and laboratory studies, electrocardiography (ECG), coronary angiography.Results. According to the criteria "Frequency and severity of hemorrhagic events, including hemorrhagic stroke", "Frequency, severity of other adverse events", there were no differences in safety between Angipure at doses of 0,40 and 0,72 mg/kg and eptifibatide. Complaints, clinical symptoms, vital signs, complete blood count, biochemical and coagulation tests, ECG in patients of different groups were similar and had unidirectional dynamics. The use of Angipure or eptifibatide was considered effective if no adverse outcomes (death, recurrent acute ischemic event, need for urgent revascularization) were observed within 30 days. There were no lethal outcomes. One repeated acute ischemic event was registered in each group. In groups of patients receiving Angipure 0,40 mg/kg and eptifibatide, urgent revascularization was required once each.Conclusion. Angipure and eptifibatide have similar safety and efficacy.
- 5 September 2023
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 22 (7) , 3573
Open AccessResults of a pilot clinical trial of the safety and efficacy of an original glycoprotein IIb/IIIa receptor inhibitor in acute coronary syndrome
Aim. To study the safety and efficacy of Angipure in acute ST-segment elevation coronary syndrome (STE-ACS) and high-risk percutaneous transluminal coronary angioplasty (PTCA) compared with eptifibatide.Material and methods. The study included 157 patients with STE-ACS. High-risk PTCA included massive or total coronary artery thrombosis, noreflow/slow-reflow phenomenon, and acute stent thrombosis. Fifty-five people received Angipure at a dose of 0,72 mg/kg, 52 — at a dose of 0,40 mg/kg, while 50 patients received eptifibatide (Integrilin). We conducted clinical and laboratory studies, electrocardiography (ECG), coronary angiography.Results. According to the criteria "Frequency and severity of hemorrhagic events, including hemorrhagic stroke", "Frequency, severity of other adverse events", there were no differences in safety between Angipure at doses of 0,40 and 0,72 mg/kg and eptifibatide. Complaints, clinical symptoms, vital signs, complete blood count, biochemical and coagulation tests, ECG in patients of different groups were similar and had unidirectional dynamics. The use of Angipure or eptifibatide was considered effective if no adverse outcomes (death, recurrent acute ischemic event, need for urgent revascularization) were observed within 30 days. There were no lethal outcomes. One repeated acute ischemic event was registered in each group. In groups of patients receiving Angipure 0,40 mg/kg and eptifibatide, urgent revascularization was required once each.Conclusion. Angipure and eptifibatide have similar safety and efficacy.
- 15 March 2023
- Published by Bionika Media in Èpidemiologiâ i Infekcionnye Bolezni. Aktual’nye Voprosy
- Vol. 1_2023, 105-115
The efficiency of different olokizumab dosage regimens in patients with mild and moderate coronavirus disease (COVID-19)
- 15 March 2023
- Published by Bionika Media in Èpidemiologiâ i Infekcionnye Bolezni. Aktual’nye Voprosy
- Vol. 1_2023, 105-115
The efficiency of different olokizumab dosage regimens in patients with mild and moderate coronavirus disease (COVID-19)
- Open Access
- 4 January 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (12) , 5149
Prevalence of oral anticoagulant therapy in clinical practice in patients hospitalized with acute ischemic stroke
Aim. To evaluate the prevalence of oral anticoagulant therapy at the outpatient and inpatient stages in patients hospitalized with ischemic stroke.Material and methods. This open observational prospective real-world study included 114 patients with atrial fibrillation (AF) hospitalized with confirmed stroke.Results. Only 26,3% of patients with AF hospitalized with a confirmed diagnosis of ischemic stroke took anticoagulants (70% — direct oral anticoagulants (DOACs), 30% — warfarin). At the same time, among those taking warfarin, only one patient had normal international normalized ratio (INR) at the time of hospitalization (INR 2,6). In all other cases, the INR was Conclusion. One of the common reasons for stroke in outpatients with AF is the refusal to take oral anticoagulants or insufficient INR control when taking warfarin.
- 4 January 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (12) , 5149
Open AccessPrevalence of oral anticoagulant therapy in clinical practice in patients hospitalized with acute ischemic stroke
Aim. To evaluate the prevalence of oral anticoagulant therapy at the outpatient and inpatient stages in patients hospitalized with ischemic stroke.Material and methods. This open observational prospective real-world study included 114 patients with atrial fibrillation (AF) hospitalized with confirmed stroke.Results. Only 26,3% of patients with AF hospitalized with a confirmed diagnosis of ischemic stroke took anticoagulants (70% — direct oral anticoagulants (DOACs), 30% — warfarin). At the same time, among those taking warfarin, only one patient had normal international normalized ratio (INR) at the time of hospitalization (INR 2,6). In all other cases, the INR was Conclusion. One of the common reasons for stroke in outpatients with AF is the refusal to take oral anticoagulants or insufficient INR control when taking warfarin.
- Open Access
- 15 December 2022
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 10 (5) , 460-471-471
CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19
The aim of the article is to study pharmacokinetic characteristics of intravenous olokizumab in patients with moderate COVID-19 to relieve a hyperinflammation syndrome.Materials and methods. The pharmacokinetic study was conducted as a part of a phase III clinical study (RESET, NCT05187793) on the efficacy and safety of a new olokizumab regimen (intravenous, at the doses of 128 mg or 256 mg) in COVID-19 patients. Plasma concentrations of olokizumab were determined by the enzyme immunoassay. The population analysis was performed using a previously developed pharmacokinetic model based on a linear two compartment.Results. The pharmacokinetic analysis included the data from 8 moderate COVID-19 patients who had been administrated with olokizumab intravenously at the dose of 128 mg. According to the analysis results in this population, there was an increase in the drug clearance, compared with the data obtained in healthy volunteers and the patients with rheumatoid arthritis: 0.435, 0.178 and 0.147 l/day, respectively. The parameters analysis within the framework of a population pharmacokinetic model showed that the main factors for the increased olokizumab clearance are a high body mass index. In addition, the presence of COVID-19 itself is an independent factor in increasing the drug clearance.Conclusion. After the intravenous olokizumab administration, an increase in the drug clearance is observed in moderate COVID-19 patients against the background of the disease course. The main contribution to the increased clearance is made by the characteristics of the population of COVID-19 patients associated with the risk of a severe disease and inflammation. When administered intravenously at the dose of 128 mg, a therapeutically significant olokizumab level was maintained throughout the acute disease phase for 28 days.
- 15 December 2022
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 10 (5) , 460-471-471
Open AccessCHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19
The aim of the article is to study pharmacokinetic characteristics of intravenous olokizumab in patients with moderate COVID-19 to relieve a hyperinflammation syndrome.Materials and methods. The pharmacokinetic study was conducted as a part of a phase III clinical study (RESET, NCT05187793) on the efficacy and safety of a new olokizumab regimen (intravenous, at the doses of 128 mg or 256 mg) in COVID-19 patients. Plasma concentrations of olokizumab were determined by the enzyme immunoassay. The population analysis was performed using a previously developed pharmacokinetic model based on a linear two compartment.Results. The pharmacokinetic analysis included the data from 8 moderate COVID-19 patients who had been administrated with olokizumab intravenously at the dose of 128 mg. According to the analysis results in this population, there was an increase in the drug clearance, compared with the data obtained in healthy volunteers and the patients with rheumatoid arthritis: 0.435, 0.178 and 0.147 l/day, respectively. The parameters analysis within the framework of a population pharmacokinetic model showed that the main factors for the increased olokizumab clearance are a high body mass index. In addition, the presence of COVID-19 itself is an independent factor in increasing the drug clearance.Conclusion. After the intravenous olokizumab administration, an increase in the drug clearance is observed in moderate COVID-19 patients against the background of the disease course. The main contribution to the increased clearance is made by the characteristics of the population of COVID-19 patients associated with the risk of a severe disease and inflammation. When administered intravenously at the dose of 128 mg, a therapeutically significant olokizumab level was maintained throughout the acute disease phase for 28 days.